Literature DB >> 19343132

Risk scoring for predicting mucositis in Indian patients with esophageal carcinoma receiving concurrent chemoradiotherapy.

C J Devaraju1, Dasappa Lokanatha, P P Bapsy, A V S Suresh, G Viswanath, B Sandhya.   

Abstract

PURPOSE: Mucositis is a common and troublesome adverse effect of concurrent chemoradiotherapy, often causing treatment interruption and compromising treatment outcome. We sought to identify predictors of mucositis in southern Indian patients treated for gastroesophageal carcinoma.
METHODS: Patients (N = 90) receiving cisplatin 40 mg/m(2) and concurrent local radiotherapy at 40 to 50 Gy for esophageal carcinoma were retrospectively assessed for predictors of mucositis. Hypothesized risk factors were age, presence of comorbid conditions, low white blood cell (WBC) count, nutritional status (assessed by serum albumin level), continuing tobacco use, elevated erythrocyte sedimentation rate (ESR) as a measure of acute inflammation, World Health Organization (WHO) performance status, and disease stage. Receiver operating characteristic (ROC) curves were drawn to identify cut-off values for risk factors, and a risk scoring model was developed.
RESULTS: On the basis of cutoff values on ROC analysis, a risk score of 1 was assigned for each risk factor as follows: age > 50 years, ESR > 3 times upper limit of normal, albumin < 3.3 g/dL, WBC < 2.5 x10(9)/L, WHO performance status > 2, and > stage III disease, with use of tobacco and presence of any comorbid condition also each being assigned a score of 1. For individual patients, a score of < 3 was associated with a 25% risk of grade 3 or 4 mucositis, whereas a score of >/= 6 was associated with 80% risk.
CONCLUSION: The scoring system is accurate in predicting the development of mucositis in southern Indian patients receiving concurrent chemoradiotherapy for esophageal carcinoma.

Entities:  

Year:  2009        PMID: 19343132      PMCID: PMC2661121     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  6 in total

1.  Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting.

Authors: 
Journal:  Oncologist       Date:  1998

2.  Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care.

Authors:  B Borowski; E Benhamou; J L Pico; A Laplanche; J P Margainaud; M Hayat
Journal:  Eur J Cancer B Oral Oncol       Date:  1994

Review 3.  Prevention and treatment of oral mucositis following cancer chemotherapy.

Authors:  J D Wilkes
Journal:  Semin Oncol       Date:  1998-10       Impact factor: 4.929

4.  Clinicopathologic effects of cancer chemotherapeutic agents on human buccal mucosa.

Authors:  J Guggenheimer; R S Verbin; B N Appel; J Schmutz
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1977-07

5.  Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.

Authors:  D J Mahood; A M Dose; C L Loprinzi; M H Veeder; L M Athmann; T M Therneau; J M Sorensen; D K Gainey; J A Mailliard; N L Gusa
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

6.  Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.

Authors:  J G Kim; S K Sohn; D H Kim; J H Baek; S B Jeon; Y S Chae; K B Lee; J S Park; J H Sohn; J C Kim; I K Park
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

  6 in total
  1 in total

1.  Frequency of chemoradiotherapy-induced mucositis and related risk factors in patients with the head-and-neck cancers: A survey in the North of Iran.

Authors:  Hamid Saeidi Saedi; Hooshang Gerami; Soheil Soltanipour; Ali Faghih Habibi; Mahmood Mirhosseyni; Sina Montazeri; Shadman Nemati
Journal:  Dent Res J (Isfahan)       Date:  2019-09-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.